Julia Prinz, Niklas Plange, Hannah Schellhase, Peter Walter, Matthias Fuest, Antonis Koutsonas, David Kuerten
{"title":"Twelve-Month Outcomes of Combined Phacoemulsification with Ab Interno Canaloplasty Versus Single-Use Dual Blade Goniotomy in Glaucoma Patients.","authors":"Julia Prinz, Niklas Plange, Hannah Schellhase, Peter Walter, Matthias Fuest, Antonis Koutsonas, David Kuerten","doi":"10.1055/a-2512-8141","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>To compare the efficacy and safety of combined phacoemulsification with ab interno canaloplasty (Phaco-AbiC) versus single-use dual blade goniotomy (Phaco-DBG).</p><p><strong>Material and methods: </strong>In this prospective consecutive case series, intraocular pressure (IOP), the number of IOP-lowering medications, the mean deviation (MD) of visual field testing, and surgery-related complications were evaluated in 25 eyes following Phaco-AbiC and 20 eyes following Phaco-DBG through 12 months of follow-up. Qualified or complete success was defined as postoperative IOP lower than 21, 18, and 16 mmHg with or without IOP-lowering medications.</p><p><strong>Results: </strong>At the 12-month follow-up, IOP was significantly reduced compared to baseline in the Phaco-AbiC (14.2 ± 2.7 versus 19.2 ± 4.7 mmHg, p < 0.001) and Phaco-DBG groups (16.7 ± 3.4 versus 19.9 ± 3.9 mmHg, p < 0.001). At the 12-month follow-up, IOP was significantly higher following Phaco-DBG than Phaco-AbiC (p = 0.011). Compared to baseline, the number of IOP-lowering medications was significantly reduced in the Phaco-AbiC (1.2 ± 1.4 versus 2.4 ± 1.0, p < 0.001) and Phaco-DBG groups (0.8 ± 0.9 versus 2.1 ± 0.9, p < 0.001) at the 12-month follow-up. For IOP lower than 16 mmHg, the complete and qualified success rate was significantly higher following Phaco-AbiC (36.0 and 76.2%, respectively) than Phaco-DBG (17.5 and 40.6%; p = 0.037; p = 0.007, respectively). No severe intra- or postoperative complications occurred.</p><p><strong>Conclusion: </strong>Both Phaco-AbiC and Phaco-DBG achieved a significant reduction in IOP and IOP-lowering medications at the 12-month follow-up. IOP was significantly lower 12 months following Phaco-AbiC than Phaco-DBG.</p>","PeriodicalId":17904,"journal":{"name":"Klinische Monatsblatter fur Augenheilkunde","volume":" ","pages":""},"PeriodicalIF":0.8000,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Klinische Monatsblatter fur Augenheilkunde","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-2512-8141","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
Twelve-Month Outcomes of Combined Phacoemulsification with Ab Interno Canaloplasty Versus Single-Use Dual Blade Goniotomy in Glaucoma Patients.
Background: To compare the efficacy and safety of combined phacoemulsification with ab interno canaloplasty (Phaco-AbiC) versus single-use dual blade goniotomy (Phaco-DBG).
Material and methods: In this prospective consecutive case series, intraocular pressure (IOP), the number of IOP-lowering medications, the mean deviation (MD) of visual field testing, and surgery-related complications were evaluated in 25 eyes following Phaco-AbiC and 20 eyes following Phaco-DBG through 12 months of follow-up. Qualified or complete success was defined as postoperative IOP lower than 21, 18, and 16 mmHg with or without IOP-lowering medications.
Results: At the 12-month follow-up, IOP was significantly reduced compared to baseline in the Phaco-AbiC (14.2 ± 2.7 versus 19.2 ± 4.7 mmHg, p < 0.001) and Phaco-DBG groups (16.7 ± 3.4 versus 19.9 ± 3.9 mmHg, p < 0.001). At the 12-month follow-up, IOP was significantly higher following Phaco-DBG than Phaco-AbiC (p = 0.011). Compared to baseline, the number of IOP-lowering medications was significantly reduced in the Phaco-AbiC (1.2 ± 1.4 versus 2.4 ± 1.0, p < 0.001) and Phaco-DBG groups (0.8 ± 0.9 versus 2.1 ± 0.9, p < 0.001) at the 12-month follow-up. For IOP lower than 16 mmHg, the complete and qualified success rate was significantly higher following Phaco-AbiC (36.0 and 76.2%, respectively) than Phaco-DBG (17.5 and 40.6%; p = 0.037; p = 0.007, respectively). No severe intra- or postoperative complications occurred.
Conclusion: Both Phaco-AbiC and Phaco-DBG achieved a significant reduction in IOP and IOP-lowering medications at the 12-month follow-up. IOP was significantly lower 12 months following Phaco-AbiC than Phaco-DBG.
期刊介绍:
-Konzentriertes Fachwissen aus Klinik und Praxis:
Die entscheidenden Ergebnisse der internationalen Forschung - für Sie auf den Punkt gebracht und kritisch kommentiert,
Übersichtsarbeiten zu den maßgeblichen Themen der täglichen Praxis,
Top informiert - breite klinische Berichterstattung.
-CME-Punkte sammeln mit dem Refresher:
Effiziente, CME-zertifizierte Fortbildung, mit dem Refresher,
3 CME-Punkte pro Ausgabe - bis zu 36 CME-Punkte im Jahr!.
-Aktuelle Rubriken mit echtem Nutzwert:
Kurzreferate zu den wichtigsten Artikeln internationaler Zeitschriften,
Schwerpunktthema in jedem Heft: Ausführliche Übersichtsarbeiten zu den wichtigsten Themen der Ophthalmologie – so behalten Sie das gesamte Fach im Blick!,
Originalien mit den neuesten Entwicklungen,
Übersichten zu den relevanten Themen.